Media Coverage

Sinovac’s COVID-19 vaccine gains China approval for emergency use in children, adolescents

Preliminary results from Phase I and II clinical trials showed the vaccine could trigger immune response in three to 17 year-old participants, and most adverse reactions were mild.

China to make up to 10 million Sinovac vaccine doses available for SA

The Numolux Group says China will make available up to 10 million doses of its Sinovac COVID-19 vaccine for South Africa. Numolux – which is Sinovac’s partner in SA – says the offer followed the South African Health Products Regulatory Authority’s approval of the two-dose jab for use in the country.

2000 SA children to take part in Sinovac Covid-19 vaccine trial for under 18s

The Sefako Makgatho Health Sciences University, Numolux, and China’s Sinovac have partnered to conduct a paediatric vaccine study on the Covid-19 vaccines for children and adolescents, aged between six months and 17 years. The vaccine study will see more than 2 000 children and teenagers take part in the study in South Africa, with seven clinical research sites across the country being utilised.?

Sinovac, Numolux in talks to build vaccine facility in South Africa: report

Amid global efforts to scale up vaccine capacity during the  pandemic, China’s Sinovac and a partner in South Africa are reportedly in talks to build a manufacturing facility in the country to produce vaccines to treat a variety of diseases.

COVID-19 in SA | Numolux says vaccine safe for children

“Coronavac is a safe vaccine. The Coronavac vaccine is safe and it induces humoral immunity”

The Sinovac-CoronaVac COVID-19 vaccine: What you need to know

How does this vaccine compare to other vaccines already in use?